Earnings Releases·Nov 5, 2026, 6:31 AM ET

InfuSystem Holdings, Inc. — Third Quarter 2026 Earnings Summary

Net revenues rose 3.0% year-over-year to $37.6 million, while net income increased to $3.2 million ($0.15 per share) from $2.3 million in the prior year; Adjusted EBITDA grew 12.5% to $9.4 million with margin expansion to 24.9%.
The company reaffirmed full-year 2026 guidance for net revenue and Adjusted EBITDA margin (low-to-mid 20% range), projecting pro-forma net revenue growth of 6% to 8% after adjusting for the GE Healthcare contract restructuring.
Significant segment divergence occurred as Patient Services revenue surged 15.4% driven by Wound Care growth, whereas Device Solutions revenue declined 16.6% due to the GE Healthcare contract restructuring, which management notes improved overall profitability through cost reductions.
Capital allocation included $5.0 million in common stock repurchases over the nine-month period, while liquidity remained strong at $64.1 million with net debt decreasing to $10.6 million.
Future outlook includes modest investments in workflow automation and software-enabled process improvements starting in Q4, alongside tapering ERP project expenses as the system transitions to ongoing optimization.